BioNeutral Group, Inc. Answering President Obama`s Call to Clean Fossil Burning Emissions and Greenhouse Gasses

NEWARK, N.J.--(Business Wire)--
BioNeutral Group, Inc. (OTCBB: BONU), a specialty life science company with a
unique combinational chemistry-based technology, reports its proprietary Ogiene
formulation can entrap and deliver the active chemical environment necessary to
eliminate a variety of noxious and toxic gases which harm the planet and
threaten all who occupy it. "This is a multi billion dollar opportunity and the
impact will be extremely positive for countless industries across our country,"
said Dr. Andy Kielbania, Ph.D., Chief Scientist at BioNeutral Group, Inc. "You
can clearly see the results of our Ogiene formulation in a toxic smoke-filled
fire situation illustrated in this field test video."

Elimination of Toxic Gases and Irritants with Ogiene
Gas Threshold Smell Levels in Test % Reduced in 10 seconds % Reduced in 1 minute
H2S (Hydrogen sulfide) 2ppb 20-50ppm 50 95
NH3 (Ammonia) 17ppm 20-50ppm 25 80
SO2 (Sulfur dioxide) 3ppm 50-150ppm 99 100
CO2 (Carbon dioxide) Na 2000ppm 10 25
Formaldehyde 0.8ppm 17-41ppm 80 99
Acetic Acid 0.4ppm 17-25ppm 20 60
ppm= parts per million; ppb = parts per billion

Dr. Vasu Kulkarni, Ph.D., who specializes in Chemical and Environmental
engineering and is a member of the Scientific Advisory Board said, "While more
studies will be required, Ogiene technology may very well prove to be one of the
most important control technologies available to address toxic and hazardous
gases and it may extend its reach to address the precursor gases that contribute
to the generation of greenhouse gas emissions."

Ogiene is rapid acting and effective on a wide variety of gases. It is non-toxic
and usually requires minimal or no cleanup after application. Ogiene is
effective in the gas phase being applied as a fog and in the liquid phase, it
can be applied as a mist or spray directly to liquid contaminates. Ogiene
products can be used as barrier curtains, in an exhaust stream (smoke stack) or
in confined static spaces and amenable to a variety of methods of application.

"This is a technology (Ogiene) which answers the call of President Obama for
inventiveness and innovation which will help power the country and address the
serious environmental issues that we all face," said President and CEO of
BioNeutral Group, Inc., Stephen J. Browand. "This technology can help reduce the
air pollution produced by the manufacturing process, create new jobs and
continue to make the country more competitive and "Green" to the environment."

About BioNeutral Group, Inc.

Headquartered at the New Jersey Institute of Technology/EDC in Newark, New
Jersey, BioNeutral Group, Inc., is a chemical technology-based Life Science
company that intends to commercialize a novel combinational chemistry-based
technology which can neutralize harmful environmental contaminants, toxins and
dangerous micro-organisms including bacteria, viruses, mold, fungi and spores.
The formulations, including Ygiene and Ogiene, which are eco-friendly and
include natural and common ingredients which are found in baby products and in
every day foods. The Company has combined these widely-used compounds in highly
specialized ways to create products that dramatically enhance disinfecting and
cleaning results; products include BioNeutralizers and ChemoNeutralizers.
BioNeutral`s proprietary platform technology has been proven effective in
surface, water and airborne applications.

More information about the Company may be found at www.bioneutralgroup.com

The video of the field test illustrating Ogiene smoke suppression may be found
at: http://www.bioneutrallabs.vipdigitalsolutions.com/images/burn_video.swf

Forward-Looking Statements

BioNeutral routinely tests its formulations against those of its competitors.
The results are published to let shareholders know how the Company's technology
compares with known formulations in the market place. Any product claim for
antimicrobial activity requires approval from the EPA or FDA, depending upon
where and how the formulations are used. The EPA and FDA have not reviewed or
confirmed the Company's data and findings. BioNeutral's antimicrobial
formulations will be marketed under the brand name Ygiene and are not yet
available for sale in the United States.

Under The Private Securities Litigation Reform Act of 1995: The statements in
the press release that relate to the Company's expectations with regard to the
future impact on the Company's results from new products in development are
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. These statements are subject to risks and
uncertainties. Words such as "expects", "intends", "plans", "may", "could",
"should", "anticipates", "likely", "believes" and words of similar import also
identify forward-looking statements. Forward-looking statements are based on
current facts and analyses and other information that are based on forecasts of
future results, estimates of amounts not yet determined and assumptions of
management. Readers are urged not to place undue reliance on the forward-looking
statements, which speak only as of the date of this release. We assume no
obligation to update any forward-looking statements in order to reflect any
event or circumstance that may arise after the date of this release. Additional
information on risks and other factors that may affect the business and
financial results of BioNeutral Group can be found in the filings of BioNeutral
Group with the U.S. Securities and Exchange Commission.

BioNeutral Group Inc.
Stephen J. Browand, President and CEO
steve@bioneutralgroup.com
or
Investor Relations:
Corporate Evolutions, Inc.
Ph: 516-482-0155
Toll Free: 877-482-0155
info@corporateevolutions.com
www.corporateevolutions.com

Copyright Business Wire 2009